Company: CSTL
Filing Date: 2025-03-28
Form Type: PRE 14A
Source: 0001447362-25-000050
Chunk: 50

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-03-28
Form: PRE 14A
Chunk 50
---
 gather input on governance matters, including our executive compensation program. As part of this process, we reached out to stockholders representing 60% of our then-outstanding common stock and held discussions with all who expressed interest. These discussions were led by our Compensation Committee Chair, with participation from certain members of the executive management team, including our CEO and our Vice President of Investor Relations & Corporate Affairs.

In 2024, these discussions covered a wide range of topics, including:

• Executive compensation

• Shareholder rights

• Overlapping metrics in short- and long-term incentives

• Desire for CEO pay to align with Company performance and size

• Enhancement to proxy disclosures

• Board structure (classification/super majority vote)

• Artificial intelligence risks

After considering stockholder feedback gathered from previous years and into the second half of 2024, as well as input from management and based in part on the Compensation Committee’s independent compensation consultant, the Compensation Committee has continued to approve changes to align our executive compensation program in 2024 with Company growth. These changes over recent years and into 2024 included:

• Continuing to expand the executive compensation disclosure in our proxy statement to respond to shareholder feedback and better describe the committee process and policy structure;

• Disclosing the material principles underlying Castle’s executive compensation policies and decisions and the most important factors relevant to changes we have made to better align our policies with investor feedback, ongoing trends and good governance practices such as:

◦ Introducing performance-based equity incentive awards in the compensation package in 2022 for our executive officers with the grants to our CEO including 50% performance-based equity;

◦ Adopting the Clawback Policy;

#### Castle Biosciences 2025 Proxy Statement49

#### Compensation Discussion and Analysis
◦ Adopting stock ownership guidelines for our directors and officers;

◦ Aligning the 2024 performance-based equity incentive to the Company’s financial metrics and commercial pipeline goals; and

◦ Shifting our annual grant cycle from the fourth quarter of the fiscal year to the first quarter of the subsequent year to (i) align with our final Board-approved budget, our fiscal year performance period, our goal setting and the reporting of our financial results and (ii) align with our commitment to performance-based equity as noted above.

Following changes we have implemented in response to shareholder feedback in previous years, investors expressed general satisfaction with the structure of our compensation for 2024. Each of the above are outlined in more detail in this Proxy Statement. The Compensation Committee will continue to consider stockholder